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Abstract
We compare two of the most successful models for the description and anal-
ysis of drug release data. The fractal kinetics approach leading to release
profiles described by a Weibull function and the fractional kinetics approach
leading to release profiles described by a Mittag-Leffler function. We used
Monte Carlo simulations to generate artificial release data from euclidean
and fractal substrates. We have also used real release data from the litera-
ture and found that both models are capable in describing release data up
to roughly 85% of the release. For larger times both models systematically
overestimate the number of particles remaining in the release device.
Keywords: Drug Release, Fractal Kinetics, Fractional Kinetics
1. Introduction
Modeling the processes involved in controlled drug release is vital for the
development of new pharmaceutical products[1]. Although several models
have been proposed for the description of drug release[2, 3, 4, 5, 6, 7, 8] ,
the main mathematical expressions used in pharmaceutics to describe the
kinetics of drug release from a large variety of devices are 1. The Peppas
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equation or the so-called power law [3]
Mt
M∞
= ktn (1)
where Mt and M∞ are the amounts of drug released at times t and infinity,
respectively. In the above k is an experimentally determined parameter,
and n is an exponent that depends on the geometry of the boundary of the
system which can be related to the drug release mechanisms. The power law
model is probably the most commonly used model of drug release since it is
rather easy to implement and is widely used to macroscopically classify the
characteristics of the release kinetics. It is usually the starting point of any
release study.
2. The Weibull model,
Mt
M∞
= 1− exp(−atb) (2)
where a , b are constants. This model has the form of a stretched exponential
and it is used in drug release studies as well as in dissolution studies. This
functional form (as well as alternative forms based on it) is derived as an
approximation in the framework of fractal kinetics [9, 10, 11, 12, 13, 14, 15,
16].
Recently, an alternative way has been proposed to mathematically de-
scribe anomalous diffusion. Diffusion in constrained and fractal topologies is
studied by the use of fractional calculus. Fractional calculus [17, 18, 11, 19]
introduces derivatives and integrals of fractional order, such as half or 3
quarters. Differential equations with fractional derivatives can be used to
describe anomalous kinetics without introducing time-dependent coefficients
as in fractal kinetics. Such equations have been shown to describe exper-
imental data of anomalous diffusion more accurately [17]. When applying
fractional calculus to the classical kinetic models one practically replaces the
usual derivatives with fractional ones. Thus, in the classical zero-order kinet-
ics model after replacing the derivative of order 1 by a derivative of fractional
order a we derive the following equation:
daX
dta
= k0 (3)
where k0 is the kinetic constant.
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The same process applied to first-order kinetics will lead to the so-called
Mittag Lefler - Fractional kinetics model.
A fractional differential equation for the drug release problem gives rise
to the expression [19]
Mt
M∞
= 1− Ea(−k1ta) (4)
where k1 is a constant, and Ea(x) is the Mittag- Leffler (ML) function
of order a. This last function is a generalization of the exponential function
whose exact behavior is obtained for a = 1.
In this paper we compare the fractal kinetics approach leading to release
profiles described by Eq. 2 with the fractional kinetics approach leading to
release profiles described by Eq. 4. We compare the functions to each other,
to their performance in describing the release from Monte Carlo simulation
data of euclidean and fractal substrates and to their description of real data
release profiles. We find that both functional forms are capable in describing
release data up to 80 − 85% of the release. Then they both systematically
overestimate the number of particles remaining in the release device. From
a purely practical point of view the Weibull model performs a little better
than the Mittag-Lefler model and fitting the release curve to the data is con-
siderably faster for the Weibull function compared to the ML function whose
“complex” form (a large sum of Gamma functions is required) is computa-
tionally more expensive.
It should be noted that all the above described models are based on kinetic
considerations. There is also the large class of , so called, mechanistic models
that are very useful when a detailed description of the underlying physical
processes is required. Mechanistic models use partial differential equations to
quantify the mechanisms involved in drug release such as water transport in
polymer tablets, swelling, drug diffusion and erosion and numerical methods
to solve the resulting equations [20, 21, 22, 23].
2. Methods
Simulation of drug release from a Cylinder
Following [24], we assume here that the drug molecules move inside the
cylinder by the mechanism of Fickian diffusion. Moreover, we assume ex-
cluded volume interactions between the particles, meaning that each molecule
occupies a volume V where no other molecule can be at the same time. We
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start with randomly distributed drug molecules and a known initial drug
concentration inside the cylinder. We first consider a three-dimensional cu-
bic lattice with L3 sites. We next define inside this cubic lattice a cylinder.
A site is uniquely defined by its 3 coordinates i, j, k. If r is the radius of the
cylinder and i2 + j2 < (r − 1)2 then the site belongs to the interior of the
cylinder and it can host drug molecules. If, on the other hand, i2 + j2 > r2
then it is outside the cylinder and it is a restricted area, and particles are
not allowed to go there. Finally, we label leak sites. We choose to label as
leak sites the sites with indices (r − 1)2 < i2 + j2 < r2 , thus defining a
cylinder leaking from its round surface but not from its top or bottom. Re-
flective boundary conditions are used for the top and bottom surface. Next,
we place a number of particles randomly on the sites of the cylinder, accord-
ing to an initial particle concentration c = 0.5, avoiding double occupancy.
This means that 50% of the sites are initially occupied by particles, and the
rest are empty. The diffusion process is simulated by selecting a particle at
random and moving it to a randomly selected nearest neighbor site. If the
new site is an empty site, then the move is allowed, and the particle is moved
to this new site. If the new site is already occupied, the move is rejected.
A particle is removed from the lattice as soon as it migrates to a site lying
within the leak area. After each particle move the time is incremented. The
increment is chosen to be 1/N , where N is the number of particles remaining
in the system. This is a typical approach in Monte Carlo simulations, and is
necessary because the number of particles continuously decreases, and thus,
the time unit characterizing the system is the mean time required for all N
particles present to move one step. We average our results using different
initial random configurations but the same parameters.
Simulation of drug release from a the percolation fractal
Following [10] and references therein, we considered percolation fractals
encapsulated on a square lattice at the percolation threshold pc = 0.593.
The fractal dimension of the percolation fractal is known to be 91/48. Cal-
culations were performed as described below. For each run we generate a
new fractal matrix assuming cyclic boundary conditions. We start with a
known initial drug concentration c = 0.5 and with randomly distributed
drug molecules inside the fractal matrix. We again assume excluded vol-
ume interactions between the particles, meaning that two molecules cannot
occupy the same site at the same time. The matrix can leak from the in-
tersection of the percolation fractal with the boundaries of the square box
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where it is embedded. The diffusion process is simulated in the same way as
for the release from the cylinder. We monitor the number of particles that
are present inside the matrix as a function of time until a fixed number of
particles (50 particles) remains in the matrix. We average our results using
different initial random configurations over at least 500 realizations.
3. Results and Discussion
In Fig.1 we compare the two basic functions i.e. the Weibull eq.1 re-
sulting from the fractal kinetics frameworks and the ML eq.4 resulting from
fractional calculus considerations.
Figure1 (Top Left) shows a Weibull function (wb) with a = 1 and b = 1
(blue line) and a Mittag-Leffler function (ml) with k1 = 1 and a = 1 (red line)
and an exponentially increasing function(black line). The three functions are
identical in this case. Fig.1 (Top Right) shows with a blue line a Weibull
function (wb) with a = 1 and b = 0.8, with black a Mittag-Leffler function
(ml) with k1 = 1 and a = 0.8 and an exponentially increasing function(black
line). We notice that the two functions begin to diverge. In Fig. 1 (Bottom
Left) we present a Weibull function with a = 1 and b = 0.5 (blue line), an ML
function with k1 = 1 and a = 0.5 (red) and an exponential function(black
line). We observe that the two functions diverge more for decreasing values
of the exponent.In Fig1 (Bottom Right) we use points to show a Mittag-
Leffler function with n1 = 1 and a = 0.5. The solid line is a fitting of a
Weibull function with a = 1.08 and b = 0.29 to the points. Observe the
descriptive power of the Weibull that leads to an almost “perfect” fitting.
This actually confirms that fractal and fractional kinetics considerations are
both valid starting points for the description of the release problem and lead
to equations that are rather close from a numerical point of view.
Figure 2 shows Monte Carlo simulation results for the number of drug
molecules N(t) inside a cylinder as a function of time. The cylinder has
a height 21 sites and a diameter of 21 sites. The initial number of drug
molecules randomly distributed in the cylider is N0 = 2, 657. Points are
the Monte Carlo data. The dashed line is a fitting of the Peppas model
N(t) = N0(1 − ktn) with n = 0.45. The solid blue line is a fitting to a
Weibull model N(t) = N0 exp(−atb) . The solid red line is a fitting to a
Mittag-Leffler model N(t) = N0Ea(−k1ta). Best fits were obtained for a
Weibull function exponent b = 0.71 and an ML exponent a = 0.81. The
Akaike Information criterion (AIC) and the Bayesian Information Criterion
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(BIC) have been calculated for each of the two functions. These two criteria
are used to measure the goodness of fit of each model to the data. The
model with the lower values of AIC and BIC is most probable to minimize
information loss and thus signify a more suitable choice [25]. Here, for the
Mittag-Leffler model we have found AIC = 579.181, BIC = 585.148 while
for the Weibull function AIC = 474.691, BIC = 480.658.
Figure 3 shows Monte Carlo simulation results for the number of drug
molecules N(t) inside percolation fractals embedded in L = 200 square lattice
as a function of time. Points are again the Monte Carlo data. The solid blue
line is a fitting to a Weibull model N(t) = N0 exp(−atb) . The solid red line
is a fitting to a Mittag-Leffler model N(t) = N0Ea(−k1ta). Best fits were
obtained for a Weibull function exponent b = 0.39 and an ML exponent a =
0.51. For the Mittag-Leffler model we have found AIC = 2651.42, BIC =
2661.13 while for the Weibull function AIC = 2205.59, BIC = 2215.3.
We observe that neither fractal nor fractional kinetics considerations can
fully describe 100% of the release from fractal matrices. In conditions of
perfect “mixing” and a Euclidean space the release profile should be purely
exponential. The departure from this exponential release in a Euclidean
space is due to the creation of a depletion zone around the release sites. The
existence of a disordered (fractal) environment is an additional reason for
the departure from first order kinetics. The relative importance of the two
mechanisms is not the same at the beginning of the release process as it is
at the end where very few drug molecules remain and the depletion effect is
not so strong. This fact is not taken care in deriving neither the Weibull nor
the Mittag-Leffler approximation where mainly only the“imperfect” mixing
due the substrate disorder is taken into account.
Next, we analyze drug release kinetics by plotting the mean release data
versus time from two characteristic cases from the literature. First we used
data obtained from fig.1 of the publication [26] concerning the release profile
of tablets of ElvesilR© 120mg diltiazem hydrochloride (Biomedica). We stud-
ied the ElvesilR© release profile under the framework of fractal and fractional
kinetics. We present our results in fig. 4. We observe that both a Weibull
function(blue line) with exponent b = 0.78 as well as a Mittag-Leffler func-
tion(red line) with a = 0.87 are capable of describing the release data. The
Power law model is shown (dashed line) for comparison. For the Mittag-
Leffler model we have found AIC = 88.9639, BIC = 91.9511 while for the
Weibull function AIC = 76.8052, BIC = 79.7924.
Finally, we analyze data of the drug release profile of 4-aminopyridine/Metolose
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90SH-4000SR matrices using HCl 0.1 N and phosphate buffer pH 7.4 as dis-
solution medium. Data were obtained from fig.5 of the publication [27]. We
present our results in figure 5. We again observe that both a Weibull func-
tion(blue line) with exponentb = 0.65 as well as a Mittag-Leffler function(red
line) with a = 0.75 are capable of describing the release data. The Power law
model is shown (dashed line) for comparison. For the Mittag-Leffler model
we have found AIC = 60.2217, BIC = 60.8134 while for the Weibull function
AIC = 57.7005, BIC = 58.2922. Both functions tend to underestimate the
release ratio above 80% of the release data in this case. The small value of the
Weibull exponent is indicative of release from a rather disordered substrate.
4. Conclusions
In this paper we compared the fractal kinetics approach leading to release
profiles described by Eq. 2 with the fractional kinetics approach leading to
release profiles described by Eq.4. We used Monte Carlo simulation data of
euclidean and fractal substrates as well as real release data from the litera-
ture and found that both functional forms are capable in describing release
data up to approximately 85% of the release. Then they both systematically
overestimate the number of particles remaining in the release device. From a
purely practical point of view the Weibull model performs a little better than
the Mittag-Leffler model concerning computational time.At the very end of
the simulations runs, the descriptive (fitting) ability of the two functions dif-
fer considerably. However, one should take into account the heterogeneous
distribution of the particles created at the end of the simulation period [10].
It seems likely that the Weibull function, which relies on a time dependent
coefficient [11] deviates less from the simulation pattern than the ML func-
tion, which is based on a differential equation of non integer order. Overall,
both functions deviate from the late stage of the simulation pattern; however,
the Weibull function exhibits smaller deviation than the ML function. This
can be seen from the visual inspection of figures 2-5 and from the fact that
the AIC and BIC estimations for the Weibull model are in all cases smaller
than that of the Mittag-Leffler model. As far as the fitting to experimental
data is concerned the Weibull function exhibits again better performance on
the basis of classical statistical criteria (correlation coefficient, distribution
of residuals , AIC) than the ML function. In short, the Weibul and the
Mittag-Leffler model are practically equally good in describing drug release
profiles. They are not reliable for the description of the final stage of the
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release process and in such cases both should be used with caution. From a
purely practical point of view the Weibull model is easier to use.
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Figure 1: (color online) Comparison of the Weibull and Mittag-Lefler functions. An
exponentially increasing function is shown as a black line for comparison in all figures.
(Top Left) The blue line shows a Weibull function (wb) with a = 1 and b = 1 while the
red a Mitage-Leffler function (ml) with n1 = 1 and a = 1. The two functions are identical
in this case and coincide with the exponential . (Top Right) The blue line shows a Weibull
function (wb) with a = 1 and b = 0.8 while the red a Mittag-Leffler function (ml) with
n1 = 1 and a = 0.8. The two functions begin to diverge. (Bottom Left) The blue line
shows a Weibull function (wb) with a = 1 and b = 0.5 while the red a Mittag-Leffler
function (ml) with n1 = 1 and a = 0.5. The two functions diverge more for decreasing
values of the exponent. (Bottom Right) The points show a Mittag-Leffler function with
n1 = 1 and a = 0.5. The solid line is a fitting of a Weibull function with a = 1.08 and
b = 0.29 to the points.Observe the descriptive power of the Weibull that leads to an almost
“perfect” fitting. In all cases time is in arbitrary units (a.u)
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Figure 2: (color online) Monte Carlo simulations: Number of drug molecules N(t) inside
a cylinder as a function of time. Points are the Monte Carlo data. The dashed line is a
fitting of the Peppas model N(t) = N0(1 − kt0.45). The solid blue line is a fitting to a
Weibull model N(t) = N0 exp(−atb).Best fit obtained for b = 0.71 . The solid red line is
a fitting to a Mittag-Leffler model N(t) = N0Ea(−k1ta).Best fit obtained for b = 0.81
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Figure 3: (color online) Monte Carlo simulations: Number of drug molecules N(t) inside
the percolation fractal as a function of time. Points are the Monte Carlo data. The solid
blue line is a fitting to a Weibull model N(t) = N0 exp(−atb) . The solid red line is a
fitting to a Mittag-Leffler model N(t) = N0Ea(−k1ta)
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Figure 4: (color online) Fitting of the Peppas model Eq.1 (dotted line), the Weibull model
Eq.2(solid blue line) and the Mittag-Leffler model Eq.4(solid red line) to release data of
ElvesilR© (Papadopoulou et al., 2006, fig 1)
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Figure 5: (color online) Fitting of the Peppas model Eq.1 (dotted line), the Weibull model
Eq.2(solid blue line) and the Mittag-Leffler model Eq.4(solid red line) to literature release
data of 4-aminopyridine/Metolose 90SH-4000SR (Juarez et al., 2001, Fig. 5)
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